Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (11-20 of 146) with videos related to

Pageof 15
Sort By:
Cell Cycle (Georgetown, Tex.)|June 7, 2021
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5pMingjun Li, Qianqian Wang, Xiaofei Zhang, et al.
Chemical Society Reviews|February 28, 2022
Angstrom-scale ion channels towards single-ion selectivityHuacheng Zhang, Xingya Li, Jue Hou, et al.
Frontiers in Medicine|August 11, 2023
Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case reportNingning Yan, Ziheng Zhang, Sanxing Guo, et al.
Frontiers in Oncology|June 18, 2024
Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experienceNingning Yan, Sanxing Guo, Siyuan Huang, et al.
Frontiers in Oncology|March 8, 2024
The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experienceNingning Yan, Sanxing Guo, Siyuan Huang, et al.
Frontiers in Oncology|July 23, 2024
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort studyShujing Shen, Xingya Li, Sanxing Guo, et al.
Frontiers in Medicine|June 9, 2023
Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case reportNingning Yan, Ziheng Zhang, Sanxing Guo, et al.
Frontiers in Endocrinology|March 13, 2026
A clinically actionable nomogram integrating HbA1c, renal function, and blood pressure for early prediction of diabetic macular edema in working-age patients with type 2 diabetesQingchun Pan, Lei Wang, Renli Huang, et al.
BMC Cancer|February 5, 2024
Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective dataNingning Yan, Huixian Zhang, Shujing Shen, et al.
Oncology Letters|February 13, 2016
Askin's tumor: 11 cases and a review of the literatureK E Zhang, Ruijuan Lu, Pan Zhang, et al.
Pageof 15

Showing results (11-20 of 146) with videos related to

Sort By:
Pageof 15
Cell Cycle (Georgetown, Tex.)|June 7, 2021
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5pMingjun Li, Qianqian Wang, Xiaofei Zhang, et al.
Chemical Society Reviews|February 28, 2022
Angstrom-scale ion channels towards single-ion selectivityHuacheng Zhang, Xingya Li, Jue Hou, et al.
Frontiers in Medicine|August 11, 2023
Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case reportNingning Yan, Ziheng Zhang, Sanxing Guo, et al.
Frontiers in Oncology|June 18, 2024
Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experienceNingning Yan, Sanxing Guo, Siyuan Huang, et al.
Frontiers in Oncology|March 8, 2024
The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experienceNingning Yan, Sanxing Guo, Siyuan Huang, et al.
Frontiers in Oncology|July 23, 2024
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort studyShujing Shen, Xingya Li, Sanxing Guo, et al.
Frontiers in Medicine|June 9, 2023
Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case reportNingning Yan, Ziheng Zhang, Sanxing Guo, et al.
Frontiers in Endocrinology|March 13, 2026
A clinically actionable nomogram integrating HbA1c, renal function, and blood pressure for early prediction of diabetic macular edema in working-age patients with type 2 diabetesQingchun Pan, Lei Wang, Renli Huang, et al.
BMC Cancer|February 5, 2024
Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective dataNingning Yan, Huixian Zhang, Shujing Shen, et al.
Oncology Letters|February 13, 2016
Askin's tumor: 11 cases and a review of the literatureK E Zhang, Ruijuan Lu, Pan Zhang, et al.
Pageof 15